Polycystic ovary syndrome (PCOS) may appear in women with hormonal imbalance. Without sufficient treatment, PCOS may lead to various health problems. There are several methods used to decrease the symptoms of PCOS, including taking medications. According to the latest studies conducted in India, it is possible to reach better results in treating PCOS if Spironolactone and Metformin are combined together.
What are Metformin and Spironolactone?
Metformin has been discovered to be effective in treating PCOS. It helps in losing some weight, restoring normal ovulatory cycles, improving insulin resistance, increasing fertility, decreasing the rate of spontaneous abortions, decreasing hyperandrogenism and the risk of gestational diabetes.
Spironolactone, a potassium-sparing diuretic, can also be used in treating PCOS. Spironolactone is able to decrease androgen levels in the body. Androgens are responsible for hair growth on the chest, face and stomach, and some women with PCOS have such symptoms. Androgens may also be the reason of acne.
Why Combine Spironolactone and Metformin?
Both medications are effectively used in treating PCOS within monotherapy, but a combination therapy may bring a better result.
Recently an open-labeled study has been conducted in India, involving 198 women with PCOS in order to find out whether the combination of Spironolactone and Metformin may be more effective in treating PSOC than monotherapy. Each woman was given 1,000 mg of metformin and 50 mg of spironolactone daily within a six-month period.
At the end of the study, the following results were achieved:
- Increased frequency of menstrual periods;
- Decreased serum testosterone;
- Decreased hirsutism;
- Decreased AUC;
- Decreased OGTT.
The results were significantly greater for the use of the combination of drugs than for either medication used separately, without a higher risk for adverse events.
Is the Combination of These Drugs Safe?
Although the combination has shown great results, it should be prescribed wisely. Using Spironolactone during pregnancy is associated with a high risk of spironolactone to feminize a male fetus, so it can only be recommended for women using highly effective methods of contraception.
Also, the study was quite short in duration and, thus, may not include all the information required. Generally, such therapy may be recommended if neither monotherapy nor alternative combination therapy shows positive results.